Phenomic AI Enters Strategic Collaborations with Boehringer Ingelheim & Astellas
Phenomic AI recently announced a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic’s expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer’s efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers.
Phenomic AI has recently entered a strategic research collaboration with Astellas for solid tumor cell therapies. For this collaboration, Phenomic and Astellas will explore the ability of antibodies, developed by Phenomic and directed at a novel target of the tumor stroma identified with Phenomic’s scTx platform, to enhance cell therapy approaches for the treatment of solid tumors.
Phenomic AI is an alumnus of OBIO's HealthMINT™ program and presented at the OBIO® Investment Summit.